Tuesday, August 5, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Cancer

AACR: PARP1-selective inhibitor demonstrates early efficacy in breast cancers with DNA repair defects

April 8, 2024
in Cancer
Reading Time: 3 mins read
0
Timothy Yap, M.B.B.S., Ph.D.
66
SHARES
597
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT
ADVERTISEMENT

ABSTRACT CT014

Timothy Yap, M.B.B.S., Ph.D.

Credit: The University of Texas MD Anderson Cancer Center

ABSTRACT CT014

SAN DIEGO – The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancers, according to results from the Phase I/II PETRA trial led by researchers at The University of Texas MD Anderson Cancer Center.

Results from the first-in-human trial were presented today at the American Association for Cancer Research (AACR) Annual Meeting 2024 by Timothy Yap, M.B.B.S., Ph.D., professor of Investigational Cancer Therapeutics and vice president and head of clinical development in the Therapeutics Discovery division.

A total of 31 patients with advanced breast cancers harboring HRR deficiency mutations received the optimal recommended dose of 60 mg of saruparib. The objective response rate was 48.8% with a median progression-free survival of 9.1 months. The drug had favorable tolerability as well as pharmacokinetic and pharmacodynamic responses.

“Saruparib is a first-in-class, highly selective and potent new generation PARP1-selective inhibitor with a wide therapeutic index,” Yap said. “The favorable safety profile of saruparib together with the low dose-reduction rate compared to approved PARP inhibitors may allow patients to remain on treatment longer at an optimal dose, offering maximal pharmacokinetic exposure and pharmacodynamic engagement, which could lead to improved efficacy.”

Poly-ADP ribose polymerase (PARP) inhibition previously was shown to be particularly effective in cancers harboring gene mutations that negatively affect DNA repair, such as BRCA1/2 mutations, because these cancers rely even more than others on PARP proteins to repair any DNA damage. By inhibiting PARP proteins, these cancers are unable to repair their DNA, leading to an inability to replicate and, ultimately, cell death.

Saruparib is a new-generation oral inhibitor selectively targeting PARP1, whereas previous PARP inhibitors targeted both PARP1 and PARP2. While these first-generation inhibitors have become the standard of care for certain cancers, the improved safety profile of saruparib could allow for more combinations with other treatments and opportunities to bring the benefits of PARP inhibitors to patients in earlier disease stages.

The trial included 141 patients who were eligible for safety analysis at a 60 mg dose. Of these, only 14.2% had to reduce dosage and just 3.5% had to discontinue treatment due to treatment-related adverse events. The most common adverse events were anemia, neutropenia, thrombocytopenia, fatigue and asthenia.

According to Yap, the safety profile of this heavily pretreated patient population compared favorably to Phase III data from approved first-generation PARP inhibitors. In follow-up to these findings, rational saruparib combination strategies currently are being tested, including clinical evaluation in the Phase III trial setting, Yap noted.

This study was funded by AstraZeneca. A full list of collaborating authors and their disclosures can be found with the abstract here.

Read this press release in the MD Anderson Newsroom. Information on all MD Anderson AACR Annual Meeting content can be found at MDAnderson.org/AACR.



Method of Research

Randomized controlled/clinical trial

Subject of Research

People

Share26Tweet17
Previous Post

Coral researchers awarded EXIST start-up funding

Next Post

How plants adjust their photosynthesis to changing light

Related Posts

blank
Cancer

AI Predicts Gastric Cancer Outcomes via CEA

August 5, 2025
blank
Cancer

Nanoparticles Transforming CAR-T Therapy: Production to Performance

August 5, 2025
blank
Cancer

Emerging Study Explores Rising Colorectal Cancer Rates and Screening Trends in Younger US Adults

August 5, 2025
blank
Cancer

Immune Landscape in Colorectal Cancer KRAS Variants

August 5, 2025
blank
Cancer

ROCK Inhibition Halts Glioblastoma by Targeting PI3K/AKT

August 5, 2025
blank
Cancer

UCLA Study Finds Mailing At-Home Test Kits Boosts Colorectal Cancer Screening Among Ages 45–49

August 4, 2025
Next Post
Synchronise two sub-processes of photosynthesis

How plants adjust their photosynthesis to changing light

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27529 shares
    Share 11008 Tweet 6880
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    939 shares
    Share 376 Tweet 235
  • Bee body mass, pathogens and local climate influence heat tolerance

    640 shares
    Share 256 Tweet 160
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    506 shares
    Share 202 Tweet 127
  • Warm seawater speeding up melting of ‘Doomsday Glacier,’ scientists warn

    310 shares
    Share 124 Tweet 78
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Most Americans Oppose Selling Fast Food Like Cheeseburgers and Fried Chicken in Hospitals, New Poll Reveals
  • For Mexican American Millennials, Personal Success Means Supporting Their Parents
  • How Aussie Skinks Outsmart Deadly Snake Venom
  • Anti-AMPAR Encephalitis Manifests as Catatonia

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 5,184 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading